Adjuvant chemotherapy
Osimertinib extendes disease-free survival regardless of prior adjuvant chemotherapy in early-stage EGFR-mutated non-small cell lung cancer
Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free...
Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer
Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...
Keytruda plus Lenvima combination for patients with certain types of advanced endometrial carcinoma - FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...
Opdivo for the adjuvant treatment of patients with high-risk urothelial carcinoma - Approved by FDA
The U.S. Food and Drug Administration ( FDA ) ha approved Opdivo ( Nivolumab ) 240 mg every two weeks...
Enfortumab vedotin in urothelial cancer: durable responses in patients who had previously received immunotherapy but were ineligible for Cisplatin in locally advanced or metastatic setting
The results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201, were...
NADIM trial: neoadjuvant chemotherapy and Nivolumab in resectable non-small-cell lung cancer
Non-small-cell lung cancer ( NSCLC ) is terminal in most patients with locally advanced stage disease. Researchers have assessed the antitumour...
Tagrisso, first adjuvant therapy for patients with non-small cell lung cancer and EGFR mutations - FDA approved
The FDA ( U.S. Food and Drug Administration ) has approved Tagrisso ( Osimertinib ) as the first adjuvant treatment...
FDA has approved Phesgo, a combination of Pertuzumab, Trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer
The Food and Drug Administration ( FDA ) has approved a new fixed-dose combination of Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf ( Phesgo...
Erdafitinib in locally advanced or metastatic urothelial carcinoma: long-term outcomes in BLC2001 trial
Erdafitinib ( Balversa ) is a pan-FGFR kinase inhibitor for treatment of adults with metastatic urothelial carcinoma ( mUC )...
Osimertinib as adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive non-small-cell lung cancer after complete tumor resection: ADAURA
Osimertinib ( Tagrisso ) is a 3rd-generation, CNS-active, epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI...
KEYNOTE-355: Pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Pembrolizumab ( Keytruda ) monotherapy has shown promising antitumor activity and manageable safety in patients with metastatic triple-negative breast cancer...
monarchE trial: Abemaciclib given with endocrine therapy has shown improvement compared to endocrine therapy alone in people whose HR+ HER2- early breast cancer is at a high risk of recurrence
Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...
Triple-negative breast cancer: Pembrolizumab in combination with chemotherapy has met primary endpoint of pathological complete response in phase 3 KEYNOTE-522 trial
The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...
Talzenna, a PARP inhibitor, approved in European Union for germline BRCA-mutated locally advanced or metastatic breast cancer
The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...
Nivolumab plus Ipilimumab - Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic...
Premenopausal patients with HER2+ early breast cancer: Letrozole - Zoledronic-acid plus Triptorelin combination is more effective than Tamoxifen plus Triptorelin in terms of disease-free survival
Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is...
Erdafitinib, a pan-FGFR inhibitor, in patients with metastatic or unresectable urothelial carcinoma and FGFR alterations
Although immune checkpoint inhibitors ( ICI ) have improved outcomes in some patients with Platinum-resistant metastatic urothelial carcinoma ( mUC...
FDA has approved Opdivo, a PD-1 checkpoint inhibitor, in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer
The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) injection, for intravenous use for the...
Cancer immunotherapy: Tecentriq approved in advanced bladder cancer as initial treatment for those unable to receive Cisplatin chemotherapy
The US Food and Drug Administration ( FDA ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...